The certification comes ahead of the company's planned launch of a microarray-based test for differentiating seasonal and non-seasonal influenza viruses.
The test, which is currently under US FDA review, is a second-generation version of OVA1 that offers improved specificity and positive predictive value.
Along with breast, ovarian, and pancreatic cancers, the "signature 3" mutation pattern was detected in around 10 percent of sequenced gastric tumors.
The company plans to launch 200 to 300 new clinical NGS panels for a variety of genetic disorders, a tenfold expansion of its current portfolio.
The firm's core technology involves electrical charge-based isolation of bacterial and fungal cells from whole blood, with in-cartridge lysis and RT-PCR.
The organizations will use genomics to further research in evolution, ecology, agriculture and aquaculture, and science education and popularization.
Among the first to combine quantitative bottom-up and top-down analyses of the same sample, the effort highlights potential benefits of including top-down data.
A team of scientists has begun to unravel the mysterious mechanisms behind metastatic organotropism, which has been puzzling scientists for over a century.
Agilent Technologies has launched the 4200 TapeStation system, a fully automated instrument that enables scientists to rapidly analyze up to 96 DNA samples at a time. The system enables end-to-end quality control of samples and libraries in any sequencing workflow, using any number of samples from one to 96, at a constant cost per sample, Agilent said in a statement. The system employs a range of prepackaged kits for RNA, DNA, and genomic DNA samples, including two new kits, the D5000 and HS D5000 ScreenTape assays, which have been specifically designed for analyzing DNA fragments and smears of up to 5,000 base pairs.
CRISPR Therapeutics has added David Altshuler to its Board of Directors, where he will hold an observer seat. Altshuler is Executive VP of Global Research and CSO at Vertex Pharmaceuticals. He joins the board following Vertex's acquisition of an ownership stake in CRISPR Therapeutics.
The money, which will be awarded over fiscal years 2017 and 2018, is being set aside for Direct to Phase II Small Business Innovation Research grants.
The companies are combining their respective software platforms to provide an end-to-end genomic testing solution for hospital labs.
For exempt carrier tests, labs will have to post information about clinical and analytical validity on their website, and educated consumers about testing limitations.